Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Enterprise Value (2016 - 2026)

Iradimed has reported Enterprise Value over the past 14 years, most recently at -$56.4 million for Q1 2026.

  • Quarterly Enterprise Value fell 12.01% to -$56.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$56.4 million through Mar 2026, down 12.01% year-over-year, with the annual reading at -$51.2 million for FY2025, 2.06% up from the prior year.
  • Enterprise Value was -$56.4 million for Q1 2026 at Iradimed, down from -$51.2 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$42.8 million in Q1 2023 and troughed at -$58.0 million in Q4 2022.
  • The 5-year median for Enterprise Value is -$51.2 million (2025), against an average of -$51.0 million.
  • Year-over-year, Enterprise Value rose 16.04% in 2023 and then fell 12.01% in 2026.
  • A 5-year view of Enterprise Value shows it stood at -$58.0 million in 2022, then grew by 14.15% to -$49.8 million in 2023, then dropped by 4.97% to -$52.2 million in 2024, then rose by 2.06% to -$51.2 million in 2025, then dropped by 10.19% to -$56.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Enterprise Value are -$56.4 million (Q1 2026), -$51.2 million (Q4 2025), and -$56.5 million (Q3 2025).